Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Treprostinil
Drug ID BADD_D02268
Description Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension.
Indications and Usage For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
Marketing Status Prescription
ATC Code B01AC21
DrugBank ID DB00374
KEGG ID D06213
MeSH ID C427248
PubChem ID 6918140
TTD Drug ID D01WUA
NDC Product Code 0703-0696; 62332-516; 68245-0008; 0703-0666; 0703-0686; 0781-3427; 58159-041; 0781-3420; 66302-120; 0703-0676; 62332-515; 66302-110; 42023-206; 42023-208; 42023-207; 62332-517; 11014-0094; 81861-0029; 62332-514; 66302-102; 54893-0024; 66302-300; 66302-302; 14501-0015; 66302-206; 0781-3425; 66302-350; 66302-105; 66302-101; 42023-209; 0781-3430; 66302-310; 66302-325
Synonyms treprostinil | ((1R,2R,3AS,9AS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3A,4,9,9A-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate | treprostinil sodium | trepostinil sodium | Orenitram | UT-15 | UT-15C | Remodulin | treprostinil diolamine | treprostinil diolamin | treprostinil diethanolamine
Chemical Information
Molecular Formula C23H34O5
CAS Registry Number 81846-19-7
SMILES CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dehydration14.05.05.0010.005750%
Delirium19.13.02.001--
Dental caries07.09.01.0010.000371%
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.0020.000556%Not Available
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.0030.007605%Not Available
Diabetes mellitus05.06.01.001; 14.06.01.001--Not Available
Diabetic ketoacidosis14.07.03.001; 05.07.03.001--Not Available
Diarrhoea07.02.01.0010.042479%
Discomfort08.01.08.003--Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Diverticulitis11.01.07.003; 07.10.02.0010.000927%Not Available
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.0070.028752%
Dizziness exertional24.06.02.018; 17.02.05.034; 02.01.02.0130.000371%Not Available
Dizziness postural24.06.02.008; 17.02.05.004; 02.01.02.0050.000556%Not Available
Drooling17.02.05.0050.000371%Not Available
Drug abuse19.07.02.010--Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dysphonia22.02.05.005; 17.02.08.004; 19.19.03.002--
Dyspnoea22.02.01.004; 02.01.03.0020.096089%
Dyspnoea at rest22.02.01.025; 02.01.03.0070.001484%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 18 Pages